EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity

Wuyan Zhang, Steven G Terra, Edward Alan Weinstein, Candace Bramson, Heidi Leister-Tebbe, Mary Lynn Baniecki, Shunjie Guan, Alex Agyemang, Simone Antonucci, Wayne Wisemandle, Jennifer Hammond iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf548 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Wuyan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research and Development, Pfizer Inc, Lake Forest, Illinois, USA. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents, Indoles. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rebound of coronavirus disease 2019 (COVID-19) is defined as return of symptoms and/or viral positivity after resolution of the initial infection. While rebound is typically mildly symptomatic and rarely associated with progression to severe disease, the benefit of repeated antiviral treatment has not been investigated.

Methods

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of a second 5-day treatment course of nirmatrelvir/ritonavir versus placebo/ritonavir in participants with symptomatic mild to moderate COVID-19 with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapid antigen test within 14 days of initial nirmatrelvir/ritonavir treatment. The primary efficacy endpoint was the change in viral SARS-CoV-2 RNA level from baseline to Day 5.

Results

The full analysis set included 436 participants assigned to treatment (292, nirmatrelvir/ritonavir; 144, placebo/ritonavir). A second 5-day course of nirmatrelvir/ritonavir resulted in a significant reduction in viral RNA levels at Day 5 compared with placebo/ritonavir (P = .0004; 95% CI, −1.09, −.32). The median time to 2 consecutive negative RAT results was 4 versus 5 days, and the median time to sustained alleviation of all targeted signs/symptoms was 8 versus 9 days in the nirmatrelvir/ritonavir and placebo/ritonavir groups, respectively. Retreatment with nirmatrelvir/ritonavir was safe and well tolerated, and there were no occurrences of COVID-19–related hospitalizations or deaths.

Conclusions

A repeated 5-day course of nirmatrelvir/ritonavir was safe and well tolerated and was associated with a faster decline in viral RNA levels. In this study, there was no clear benefit of retreatment because rebound was transient and mild and did not lead to severe COVID-19. Clinical Trials Registration NCT05567952; https://clinicaltrials.gov/study/NCT05567952.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsIndolesHumansMaleMiddle AgedFemaleDouble-Blind MethodSARS-CoV-2COVID-19AdultRNA, ViralRetreatmentAgedTreatment OutcomeProlineLactamsLeucineNitriles

Stichwörter der Autor:innen

COVID-19nirmatrelvirreboundretreatmentritonavir

Substanzen

RitonavirAntiviral AgentsnirmatrelvirRNA, ViralIndolesProlineLactamsLeucineNitriles

Autor:innen und Institutionen

  • Pfizer Research and Development, Pfizer Inc, Lake Forest, Illinois, USA.
  • Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA.
  • Pfizer Research and Development, Pfizer Inc, New York, New York, USA.
  • Pfizer Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Pfizer Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Pfizer Research and Development, Pfizer Ltd, Tadworth, United Kingdom.

ORCID-Profile: Jennifer Hammond

Förderung

  • Pfizer

Zitieren

APA

Zhang, W., Terra, S. G., Weinstein, E. A., Bramson, C., Leister-Tebbe, H., Baniecki, M. L., Guan, S., Agyemang, A., Antonucci, S., Wisemandle, W., & Hammond, J. (2026). Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf548

Vancouver

Zhang W, Terra SG, Weinstein EA, Bramson C, Leister-Tebbe H, Baniecki ML, et al. Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf548

BibTeX
@article{Zhang2026,
  author = {Zhang, Wuyan and Terra, Steven G and Weinstein, Edward Alan and Bramson, Candace and Leister-Tebbe, Heidi and Baniecki, Mary Lynn and Guan, Shunjie and Agyemang, Alex and Antonucci, Simone and Wisemandle, Wayne and Hammond, Jennifer},
  title = {Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf548}
}
Kostenlos starten →